Sold as Vasotec. Every FDA application for this active ingredient: 1 branded and 6 generic.
As of Nov 15, 2026, FDA lists 7 applications for Enalaprilat (sold as Vasotec), first approved Feb 9, 1988, with 0 new uses approved and 0 published complete response letters.
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Chronic Kidney Disease, Type 2 Diabetes · Baylor Research Institute | Phase 4 | Enrolling by invitation | Apr 23, 2026 |
| The Assessment of Partial Guideline-Directed Medical Therapy Down Titration in Heart Failure in Remission.Heart Failure · Ziekenhuis Oost-Limburg | Phase 4 | Recruiting | Apr 7, 2026 |
| Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension StudyHypertension, Postpartum Preeclampsia · The Cleveland Clinic | Not applicable | Recruiting | Jan 23, 2026 |
| Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort StudyPost-stroke Pneumonia · First Teaching Hospital of Tianjin University of Traditional Chinese Medicine | — | Not yet recruiting | Dec 4, 2025 |
| Cardiovascular Protection After Preeclampsia With EnalaprilPreeclampsia, Hypertensive Disorder of Pregnancy · Women and Infants Hospital of Rhode Island | Phase 3 | Recruiting | Oct 30, 2025 |
| Postpartum Evaluation of Nifedipine and Enalapril for HypertensionHypertension in Pregnancy · Nebraska Methodist Health System | Phase 4 | Recruiting | Jun 15, 2025 |
| A Study of Enalapril in Treatment of Venous MalformationsVenous Malformation, Pain · Oslo University Hospital | Phase 2 | Recruiting | Jan 23, 2025 |
| Feb 9, 1988 | VasotecNDA 19309 · New active ingredient | Biovail Labs Intl | 26 | Discontinued |
| Aug 22, 2000 | EnalaprilatANDA 75456 | Hospira | 0 | Discontinued |
| Aug 22, 2000 | EnalaprilatANDA 75458 | Hospira | 3 | Discontinued |
| Aug 22, 2000 | EnalaprilatANDA 75571 | Hospira | 2 | Discontinued |
| Aug 22, 2000 | EnalaprilatANDA 75578 | Dr Reddys | 4 | Marketed |
| Aug 22, 2000 | EnalaprilatANDA 75634 | Chartwell Injectable | 2 | Marketed |
| Dec 23, 2008 | EnalaprilatANDA 78687 | Hikma Farmaceutica | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA